www.fdanews.com/articles/125342-eli-lilly-licenses-testosterone-drug-from-acrux
Eli Lilly Licenses Testosterone Drug From Acrux
March 16, 2010
Eli Lilly & Co. has acquired the rights to market Acrux’s experimental testosterone
deficiency treatment worldwide in a deal potentially worth more than $335 million, the companies said.
Forbes
Forbes